HAS-BLED Score for Major Bleeding Risk
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- Moderate Risk2–2
- High Risk3–9
The HAS-BLED Score for Major Bleeding Risk calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include hypertension. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.
Clinical Indication
The HAS-BLED Score for Major Bleeding Risk is indicated for bedside clinical practice to support Estimates 1-year risk of major bleeding for patients on anticoagulation to assess quality of atrial fibrillation care. Used with CHA2DS2-VASc score to balance stroke vs bleeding risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention. Clinical exclusion: Do not use HAS-BLED alone to withhold anticoagulation.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
HAS-BLED Score = Hypertension (1) + Abnormal renal function (1) + Abnormal liver function (1) + Stroke (1) + Bleeding (1) + Labile INR (1) + Elderly (1) + Drugs (1) + Alcohol (1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| hypertension | string | Yes | Hypertension (uncontrolled, systolic blood pressure >160 mmHg) |
| abnormal_renal_function | string | Yes | Abnormal renal function (dialysis, renal transplant, or serum creatinine >2.26 mg/dL or >200 μmol/L) |
| abnormal_liver_function | string | Yes | Abnormal liver function (cirrhosis or bilirubin >2x normal with AST/ALT/AP >3x normal) |
| stroke_history | string | Yes | Previous stroke (ischemic or hemorrhagic) |
| bleeding_history | string | Yes | Prior major bleeding or predisposition to bleeding (anemia, bleeding diathesis, etc.) |
| labile_inr | string | Yes | Labile INR (unstable/high INRs, time in therapeutic range <60%) |
| elderly | string | Yes | Elderly (age >65 years) |
| drugs | string | Yes | Drugs predisposing to bleeding (antiplatelet agents, NSAIDs) |
| alcohol | string | Yes | Alcohol use (≥8 drinks per week) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | Low bleeding risk |
| 2–2 | Moderate Risk | Moderate bleeding risk |
| 3–9 | High Risk | High bleeding risk |
Evidence-Based References (EBM)
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134.DOI: 10.1378/chest.10-0134
- Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024.DOI: 10.1016/j.jacc.2010.09.024
- Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012 Aug 28;60(9):861-7. doi: 10.1016/j.jacc.2012.06.019.DOI: 10.1016/j.jacc.2012.06.019